California State Teachers Retirement System Lowers Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

California State Teachers Retirement System cut its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 2.5% in the 1st quarter, HoldingsChannel reports. The firm owned 196,863 shares of the biopharmaceutical company’s stock after selling 4,953 shares during the period. California State Teachers Retirement System’s holdings in Alnylam Pharmaceuticals were worth $65,136,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of ALNY. Geode Capital Management LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 6.1% during the 4th quarter. Geode Capital Management LLC now owns 2,650,722 shares of the biopharmaceutical company’s stock worth $1,056,884,000 after acquiring an additional 151,480 shares during the last quarter. Norges Bank bought a new position in Alnylam Pharmaceuticals in the fourth quarter valued at $895,816,000. Orbis Allan Gray Ltd raised its position in Alnylam Pharmaceuticals by 29.8% during the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock valued at $691,771,000 after purchasing an additional 486,489 shares in the last quarter. Legal & General Group Plc raised its position in Alnylam Pharmaceuticals by 8.3% during the fourth quarter. Legal & General Group Plc now owns 961,496 shares of the biopharmaceutical company’s stock valued at $382,339,000 after purchasing an additional 73,716 shares in the last quarter. Finally, AQR Capital Management LLC lifted its stake in Alnylam Pharmaceuticals by 23.6% during the fourth quarter. AQR Capital Management LLC now owns 919,959 shares of the biopharmaceutical company’s stock worth $365,822,000 after purchasing an additional 175,951 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insider Activity

In related news, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the transaction, the director owned 1,582 shares in the company, valued at $473,302.76. The trade was a 70.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is owned by insiders.

Alnylam Pharmaceuticals Price Performance

Shares of Alnylam Pharmaceuticals stock opened at $205.48 on Friday. The firm has a market cap of $27.43 billion, a PE ratio of 56.14 and a beta of 0.27. Alnylam Pharmaceuticals, Inc. has a 12-month low of $197.81 and a 12-month high of $495.55. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94. The company’s fifty day simple moving average is $289.80 and its two-hundred day simple moving average is $312.07.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, beating the consensus estimate of $0.87 by $1.12. The firm had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The company’s quarterly revenue was up 96.4% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.44) earnings per share. As a group, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post 7.35 EPS for the current year.

More Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Alnylam reported second-quarter adjusted EPS of $1.84, above the $1.63 consensus estimate, while revenue rose 66.9% year over year to $1.29 billion. The company also highlighted strong demand and performance from its TTR medicines. Alnylam Q2 2026 Earnings Call Shows TTR Strength
• Positive Sentiment: Needham lowered its price target to $357 from $510 but maintained a Buy rating, indicating that the analyst still sees substantial long-term upside despite the revised near-term outlook. Benzinga
• Neutral Sentiment: The company forecast 2026 revenue of $5.3 billion to $5.7 billion, versus analyst expectations of approximately $5.6 billion. The range remains broadly near consensus, but the lower end signals reduced confidence in the pace of growth.
• Negative Sentiment: Alnylam lowered its fiscal 2026 guidance as demand for second-line use of Amvuttra normalized. Investors appear more focused on the weaker forward outlook and potential moderation in commercial momentum than on the quarterly EPS beat. Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks
• Negative Sentiment: A shareholder-rights law firm announced an investigation into possible securities-law violations. Although the announcement does not establish wrongdoing, it adds legal and reputational uncertainty following the guidance reduction. Securities Fraud Investigation Into Alnylam Pharmaceuticals

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on ALNY shares. Wells Fargo & Company upped their price objective on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a report on Friday, May 1st. HC Wainwright boosted their target price on Alnylam Pharmaceuticals from $470.00 to $485.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. JPMorgan Chase & Co. cut their target price on Alnylam Pharmaceuticals from $420.00 to $400.00 and set an “overweight” rating for the company in a research note on Wednesday, July 22nd. Citigroup initiated coverage on shares of Alnylam Pharmaceuticals in a research report on Tuesday, May 19th. They set a “buy” rating and a $380.00 price target on the stock. Finally, Royal Bank Of Canada decreased their price target on shares of Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating on the stock in a research note on Friday, May 1st. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $445.48.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.